Phospholipid-Based Prodrugs for Colon-Targeted Drug Delivery: Experimental Study and In-Silico Simulations.
Phospholipase A2
colon-targeted drug delivery
molecular dynamics
prodrug approach
ulcerative colitis
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
16 Apr 2019
16 Apr 2019
Historique:
received:
01
03
2019
revised:
07
04
2019
accepted:
08
04
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
19
4
2019
Statut:
epublish
Résumé
In ulcerative colitis (UC), the inflammation is localized in the colon, and one of the successful strategies for colon-targeting drug delivery is the prodrug approach. In this work, we present a novel phospholipid (PL)-based prodrug approach, as a tool for colonic drug targeting in UC. We aim to use the phospholipase A
Identifiants
pubmed: 30995772
pii: pharmaceutics11040186
doi: 10.3390/pharmaceutics11040186
pmc: PMC6523355
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : United States-Israel Binational Science Foundation
ID : 2015365
Références
Scand J Clin Lab Invest. 1999 Jul;59(4):279-87
pubmed: 10463466
Am J Gastroenterol. 2000 Jul;95(7):1628-36
pubmed: 10925961
Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S15-27
pubmed: 11033424
Chem Phys Lipids. 2000 Oct;107(2):143-57
pubmed: 11090844
N Engl J Med. 2002 Aug 8;347(6):417-29
pubmed: 12167685
J Pharm Pharm Sci. 2003 Jan-Apr;6(1):33-66
pubmed: 12753729
Mol Cancer Ther. 2004 Nov;3(11):1451-8
pubmed: 15542784
Crit Rev Food Sci Nutr. 2005;45(4):251-8
pubmed: 16047493
Expert Opin Drug Deliv. 2005 May;2(3):451-63
pubmed: 16296767
Expert Opin Drug Deliv. 2006 Jan;3(1):111-25
pubmed: 16370944
Mol Carcinog. 2007 Feb;46(2):106-16
pubmed: 17091473
J Control Release. 2007 May 14;119(1):86-93
pubmed: 17382425
CNS Drug Rev. 2007 Summer;13(2):260-77
pubmed: 17627676
Anticancer Res. 2007 Sep-Oct;27(5A):3179-85
pubmed: 17970059
J Control Release. 2008 Feb 18;126(1):1-9
pubmed: 18082281
Nat Rev Drug Discov. 2008 Mar;7(3):255-70
pubmed: 18219308
Pathol Res Pract. 2010 Feb 15;206(2):73-82
pubmed: 19362431
Science. 1991 Nov 15;254(5034):1007-10
pubmed: 1948070
J Vis Exp. 2010 Jan 19;(35):null
pubmed: 20087313
Biochimie. 2010 Jun;92(6):601-10
pubmed: 20362028
Int J Pharm. 2010 Aug 16;395(1-2):44-52
pubmed: 20546856
Expert Rev Clin Immunol. 2010 Jul;6(4):543-50
pubmed: 20594127
J Pharm Sci. 2010 Dec;99(12):4755-65
pubmed: 20821387
J Liposome Res. 2011 Dec;21(4):296-305
pubmed: 21438721
Eur J Pharm Sci. 2012 Mar 12;45(4):408-20
pubmed: 21946258
N Engl J Med. 2011 Nov 3;365(18):1713-25
pubmed: 22047562
J Vis Exp. 2012 Feb 01;(60):null
pubmed: 22331082
Nanomedicine (Lond). 2012 Oct;7(10):1507-19
pubmed: 22709347
Science. 1990 Dec 14;250(4987):1563-6
pubmed: 2274788
FASEB J. 2012 Aug;26(8):3306-20
pubmed: 22767227
PLoS One. 2013;8(2):e57081
pubmed: 23451150
Expert Opin Drug Deliv. 2013 Sep;10(9):1275-86
pubmed: 23721560
ACS Med Chem Lett. 2010 Aug 31;1(9):540-5
pubmed: 24900245
Chem Phys Lipids. 2014 Oct;183:110-6
pubmed: 24905766
Molecules. 2014 Oct 14;19(10):16489-505
pubmed: 25317578
Nanomedicine. 2015 Jul;11(5):1117-32
pubmed: 25784453
AAPS PharmSciTech. 2015 Aug;16(4):731-41
pubmed: 26070545
Curr Top Med Chem. 2016;16(23):2543-8
pubmed: 27086789
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Nature. 2016 Dec 21;540(7634):S97
pubmed: 28002398
Mol Pharm. 2017 May 1;14(5):1325-1338
pubmed: 28080053
Eur J Pharm Sci. 2017 Oct 15;108:78-85
pubmed: 28627471
J Comput Aided Mol Des. 2017 Nov;31(11):1021-1028
pubmed: 29101519
Drug Deliv Transl Res. 2019 Apr;9(2):595-614
pubmed: 29611113
Nat Rev Drug Discov. 2018 Aug;17(8):559-587
pubmed: 29700501
J Control Release. 2018 Nov 28;290:165-179
pubmed: 30142410
Med Res Rev. 2019 Mar;39(2):579-607
pubmed: 30320896
Pharmaceutics. 2018 Nov 01;10(4):null
pubmed: 30388756
Gut. 1994 Nov;35(11):1593-8
pubmed: 7828979
Am J Gastroenterol. 1993 Jul;88(7):1076-80
pubmed: 8317409
Gut. 1996 Nov;39(5):698-704
pubmed: 9014769
Gut. 1997 Jan;40(1):95-101
pubmed: 9155583